Embecta logo

EmbectaNASDAQ: EMBC

Profile

Sector:

Healthcare

Country:

United States

IPO:

22 March 2022

Next earnings report:

21 November 2024

Last dividends:

27 August 2024

Next dividends:

N/A
$812.15 M
-69%vs. 3y high
71%vs. sector
-56%vs. 3y high
18%vs. sector
-121%vs. 3y high
11%vs. sector
-68%vs. 3y high
19%vs. sector

Price

regular market | 9 min ago
$14.07-$0.26(-1.78%)
$272.50 M$276.99 M
$272.50 M$14.70 M

Analysts recommendations

Institutional Ownership

EMBC Latest News

Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
zacks.com04 September 2024 Sentiment: POSITIVE

EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.

embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes
globenewswire.com03 September 2024 Sentiment: POSITIVE

embecta has received 510(k) clearance from the FDA for its proprietary disposable insulin delivery system, a patch pump with a 300-unit insulin reservoir.

embecta to Participate in Investor Events
globenewswire.com22 August 2024 Sentiment: POSITIVE

PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events:

Embecta Corp. (EMBC) Tops Q3 Earnings and Revenue Estimates
zacks.com09 August 2024 Sentiment: POSITIVE

Embecta Corp. (EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago.

Embecta Corp. Reports Third Quarter Fiscal 2024 Financial Results
globenewswire.com09 August 2024 Sentiment: POSITIVE

PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2024.

embecta Announces Quarterly Cash Dividend
globenewswire.com09 August 2024 Sentiment: POSITIVE

PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024.

embecta to Report Fiscal Third Quarter 2024 Financial Results
globenewswire.com18 July 2024 Sentiment: POSITIVE

PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, Aug 9, 2024.

embecta-sponsored Abstracts Presented at American Diabetes Association's 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir
globenewswire.com24 June 2024 Sentiment: POSITIVE

PARSIPPANY, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, presented two abstracts at the American Diabetes Association's 84th Scientific Sessions that point to the potential for adults with type 2 diabetes (T2D) to better manage insulin delivery through a patch pump with a larger, 300-unit (u) insulin reservoir, which could provide longer wear times and fewer disposable patches over time.

Trade Winds Turning: 3 Stocks Poised to Gain from Biden's China Tariffs
investorplace.com21 May 2024 Sentiment: POSITIVE

The White House recently confirmed increased tariffs on various Chinese goods. Investors and traders are on the lookout for stocks to benefit from China tariffs as the change could significantly impact many industries, including the U.S. automotive industry, electric vehicles (EVs) and others.

Embecta (EMBC) CEO on Diabetes Treatment Market
youtube.com17 May 2024 Sentiment: POSITIVE

Embecta (EMBC) CEO Dev Kurdikar sits down with Oliver Renick to provide an overview of the company and delve into its second quarter earnings. Additionally, he addresses the influence of GLP-1 medications.

  • 1(current)

What type of business is Embecta?

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

What sector is Embecta in?

Embecta is in the Healthcare sector

What industry is Embecta in?

Embecta is in the Medical Instruments & Supplies industry

What country is Embecta from?

Embecta is headquartered in United States

When did Embecta go public?

Embecta initial public offering (IPO) was on 22 March 2022

What is Embecta website?

https://www.embecta.com

Is Embecta in the S&P 500?

No, Embecta is not included in the S&P 500 index

Is Embecta in the NASDAQ 100?

No, Embecta is not included in the NASDAQ 100 index

Is Embecta in the Dow Jones?

No, Embecta is not included in the Dow Jones index

When was Embecta the previous earnings report?

No data

When does Embecta earnings report?

The next expected earnings date for Embecta is 21 November 2024